Recursion Pharmaceuticals (RXRX) PT Raised to $5.50 at Morgan Stanley
Tweet
Share
E-mailGet Alerts RXRX Hot Sheet
Price: $3.16 -4.53%
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley analyst Sean Laaman raised the price target on Recursion Pharmaceuticals (NASDAQ: RXRX) to $5.50 (from $5.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- LG Electronics India (LGEL:IN) PT Raised to INR1,815 at ICICI Securities
- KP Tissue Inc. (KPT:CN) (KPTSF) PT Raised to Cdn$13.50 at Desjardins
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
